Ceva posts strong double-digit organic growth once again in first half of 2016 >

Consolidated sales of the Ceva Group reached €455m at the end of June 2016.

Ceva acquires Biovac >

Move will reinforce group’s AMR strategy to find alternative solutions to use of antibiotics.

Ceva Posts Strong Double-Digit growth again in 2014 >

Consolidated sales of the Ceva Group reached €766m at the end of 2014, representing growth of 23% and +14.1% at a constant perimeter and exchange rates.

Another investment of HUF 2 billion from Ceva-Phylaxia >

Ceva-Phylaxia, one of the veterinary market leaders expands its vaccine production plant again.

50 billionth domestic poultry vaccine reaches completion >

As a market leader, the so-called immune complex vaccines against one of the most frequent catching disease that affects chickens are produced in Hungary.

Press Release: The new canine disease can be prevented >

Press Release: The big tick map is to come >

Ceva records double digit growth for 3rd. successive year >

14% growth pushes sales beyond 600 M€ for first time

Innovation drives Ceva's growth >

You can find in the attachment the mid-year result 2012 of the Ceva Group